| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 180.3 | 159.4 |
| Profit before tax | 38.6 | 12.1 |
| Net income | 37.9 | 12.9 |
| EPS (diluted, $ a share) | $0.14 | $0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +193.9% |
|---|---|
| Revenue, year on year | +13.1% |
| Operating margin | 29.6% |
10-Q filed with the SEC, NASDAQ: BCRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Biocryst Pharmaceuticals Inc: key numbers
- Share price
- $7.50Close, Nov 17
- Market cap
- $1.93B
- Shares outstanding
- 257.3MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biocryst Pharmaceuticals Inc
All →Biocryst Pharmaceuticals Financial Results
BioCryst reported Q3 2026 total net revenue of $180.3 million, driven by $174.8 million in ORLADEYO sales, and achieved an operating profit of $53.3 million. The company increased its full-year total revenue guidance to $715-$730 million and highlighted the recent FDA approval of ORLADEYO oral pellets for patients aged 12 and older.
- Term
- 3 years
“In the third quarter, we delivered continued growth of ORLADEYO and strong profitability while broadening the foundation for our long-term success.”
Charlie Gayer, President and Chief Executive Officer
“This progress across our business increases our confidence in our ability to drive sustainable growth and lasting value for patients and shareholders.”
Charlie Gayer, President and Chief Executive Officer